Skip to content
Menu

Rani Therapeutics Holdings, Inc. RANI

Full chart Compare
Set alert

Price alert · RANI

All alert types
0.58 USD -0.07 (-10.42%)

Regular-session close

0.59 +0.01 +1.72%

After hours · Nov 19, 6:12 PM ET

0.56 Day range 0.6503
0.502 52-week range 1.82
YTD
-56.99%
1 year
-66.82%

5D +0.0719 (+13.48%)

0.50000.55000.6000FriMonTueWedThu0.6054
Market cap
67.05M
EPS (ttm)
-0.07
Shares out
33.31M
Forward P/E
-1.41
YTD return
-56.99%
1-year return
-66.82%
50-day average
2.15
200-day average
3.43
Volume
535.31K
Avg volume
553.26K
Open
0.65
Previous close
0.6481
Day's range
0.56 – 0.6503
52-week range
0.502 – 1.82
Beta
0.11
Price target
11.50 (+1880.7%)

Key statistics

Enterprise value
75.89M
Price / book
2.87
Free cash flow
-22.84M
Total cash
30.90M
Total debt
35.25M
Return on equity
-225.35%
Short % of float
7.72%

Fundamental scorecard

9 of 25 checks passed on RANI’s reported financials

ValueGrowthProfitabilityHealthDividend

9of 25 checks passed

  • Value 2 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
RANI Revenue — quarterly 1.71M
RANI Net income — quarterly -7.73M
RANI EPS — quarterly -0.04

Earnings

RANI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.22-0.24-0.02-9.09%
Aug 6, 2024Jun 1, 2024-0.29———
Aug 6, 2024Jun 1, 2024-0.29-0.26+0.03+10.34%
May 6, 2024Mar 1, 2024-0.23———
May 6, 2024Mar 1, 2024-0.23-0.29-0.06-26.09%
Mar 20, 2024Dec 1, 2023-0.31-0.27+0.04+12.90%

Upgrades / downgrades

RANI analyst upgrades and downgrades
DateFirmActionFromTo
Nov 19, 2024HC Wainwright & Co.reitBuyBuy
Oct 18, 2024HC Wainwright & Co.reitBuyBuy
Aug 16, 2024HC Wainwright & Co.mainBuyBuy
Aug 2, 2024Oppenheimerinit—Outperform
Jun 25, 2024HC Wainwright & Co.reitBuyBuy
Jun 14, 2024Maxim Groupinit—Buy

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on RANI — it syncs with the Stock Master app.

Insider holders

RANI insider holders
InsiderRelationLatest transactionDateShares held
BUTEL JEAN LUCDirectorPurchaseNov 16, 202350,500
GROEN ERICGeneral CounselStock Award(Grant)Mar 26, 2023163,216
HASHIM MIROfficerStock Award(Grant)Mar 26, 2023273,265
IMRAN TALATChief Executive OfficerPurchaseDec 8, 2024494,751
MCKINLEY KATEOfficerPurchaseDec 12, 202417,960
NANAVATY MAULIKDirectorPurchaseNov 15, 202311,517

Institution ownership

RANI institution ownership
Holder% heldSharesValueReported
Armistice Capital, LLC7.73%2,574,0003.66MSep 29, 2024
Vanguard Group Inc2.13%709,8281.01MSep 29, 2024
Nan Fung Group Holdings Limited1.48%493,584700.89KSep 29, 2024
Alphabet Inc.1.35%448,492636.86KSep 29, 2024
United Services Automobile Association0.91%302,743429.89KSep 29, 2024
Stifel Financial Corporation0.81%269,768383.07KSep 29, 2024

Fund ownership

RANI fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.56%518,702736.56KSep 29, 2024
Vanguard Extended Market Index Fund0.52%172,976245.63KSep 29, 2024
Fidelity Extended Market Index Fund0.27%88,844126.16KOct 30, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.21%71,500101.53KSep 29, 2024
Fidelity Total Market Index Fund0.08%26,16737.16KOct 30, 2024
Northern Small Cap Core Fund0.07%23,70033.65KSep 29, 2024